Second or 3rd line Nivolumab (Nivo) versus Nivo plus Ipilimumab (Ipi) in Malignant Pleural Mesothelioma (MPM) patients: updated results of the IFCT-1501 MAPS2 randomized phase 2 trial.

  • Etude concernée: IFCT-1501
  • Auteurs / Authors: Zalcman G, Mazieres J, Greillier L, Lantuejoul S, Dô P, Bylicki O, Monnet I, Corre R, Audigier-Valette C, Locatelli-Sanchez M, Molinier O, Thiberville L, Urban T, Planchard D, Ligeza-Poisson C, Amour A, Morin F, Moro-Sibilot D, Scherpereel A
  • Journal / Conference: ESMO
  • Année / Year: 2017
  • PMID: Oral abstract
  • Lien vers la publication: https://www.annalsofoncology.org/article/S0923-7534(20)39174-2/fulltext